welcomes you to the new, improved website!Puzzling subgroup from the GALILEO trial, which appears in the same issue of the periodical as an article that discredits the use of rivaroxaban as thromboprevention strategy :
https://www.nejm.org/doi/full/10.1056/NEJMoa1911425?query=recirc_curatedRelated_article,
And yet, in this particular subgroup, a subclinical benefit on leaflet mobility is being suggested! It would appear that the GALILEO will be discussed at length and in detail in the months and years to come.
You are here:
Reduced Leaflet Motion After Transcatheter Aortic Valve Replacement
Submitted by: Aristotle Protopapas
Source: The New England Journal of Medicine
Keywords:
Author(s): Ole De Backer, George D. Dangas, Hasan Jilaihawi, Jonathon A. Leipsic, Christian J. Terkelsen, Raj Makkar, Annapoorna S. Kini, Karsten T. Veien, Mohamed Abdel-Wahab, Won-Keun Kim, Prakash Balan, Nicolas Van Mieghem, Ole N. Mathiassen, Raban V. Jeger, Martin Arnold, Roxana Mehran, Ana H.C. Guimarães, Bjarne L. Nørgaard, Klaus F. Kofoed, Philipp Blanke, Stephan Windecker, and Lars Søndergaard, M.D., D.M.Sc. for the GALILEO-4D Investigators
Abstract
